NEW YORK (GenomeWeb News) – PamGene International announced today that it has entered into a co-marketing pact with Invitrogen covering nuclear hormone receptor products.
Under the alliance, the firms will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s microarray-based nuclear hormone receptor screening tools including its PamChip applications and PamStation instruments.
According to PamGene, the combination of products provides researchers with a complete offering for compound screening in the areas of cancer, diabetes, and heart disease.
Terms of the alliance were not disclosed.